Experts Establish Psoriasis Biologic Tapering Algorithm
An international panel published a new 2-step protocol in September 2026 to standardize psoriasis treatment dose reductions.
Updated on Oct. 20, 2026 in Diabetes
Live Poll
Should doctors prioritize expert consensus guidelines when clinical trial data is limited or absent?
In September 2026, an international panel of 62 dermatologists published a consensus in the Journal of the European Academy of Dermatology and Venereology establishing a standardized 2-step algorithm for tapering psoriasis biologics. The protocol aims to provide a consistent framework for managing dose reduction in patients with well-controlled disease.
Why it matters
The study was conducted to address the lack of uniform clinical practices for dose reduction in patients successfully managing their psoriasis with biologic therapies. By establishing expert consensus, the findings offer a structured approach to clinical decision-making for long-term care.
The panel utilized a modified eDelphi process with a 9-point Likert scale to reach consensus, requiring at least 70% agreement and under 15% disagreement. The resulting algorithm applies to adalimumab, etanercept, ustekinumab, and newer inhibitor classes.
The players
Journal of the European Academy of Dermatology and Venereology
This is a prominent peer-reviewed medical publication that covers clinical research and advancements in dermatology.
The details
The development process involved three consensus rounds and a digital meeting to refine 11 distinct statements regarding medication management. Because the recommendations rely on expert opinion rather than prospective clinical trials, the panel highlighted that the guidelines serve as a practical starting point for clinicians rather than a replacement for future trial outcomes.
Timeline
The consensus study was published in the Journal of the European Academy of Dermatology and Venereology in 2026.
The Big Picture
This consensus protocol updates existing European Academy of Dermatology and Venereology guidelines by introducing a formal 2-step framework for biologic dose management. It shifts the field toward standardized maintenance care by filling the gap where definitive clinical trial data is currently missing.
Patients currently using biologics for psoriasis may find that their dermatologists have new, standardized guidance to discuss regarding long-term maintenance and potential dose adjustments. These protocols are designed to help doctors safely reduce medication frequency for patients who have achieved stable, well-controlled skin health.
The takeaway
This new algorithm provides clinicians with a consistent, expert-backed methodology for navigating the complex process of biologic dose reduction. Patients and providers should view these steps as an evolving framework that will be further validated by future prospective clinical studies.
Further reading
Learn more about the latest research and clinical standards in our Diabetes section.
Source note: This article includes information reported by Ajmc.
Live Poll
Should doctors prioritize expert consensus guidelines when clinical trial data is limited or absent?
